AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22090363
Drug: Oral losmapimod
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral losmapimod 7.5 mg twice daily
Trial: 22090363
Drug: Inhaled salmeterol/fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol/fluticasone propionate 50 µg/500 µg combination (SFC)
Trial: 20384393
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg single oral dose in ESRD patients
Trial: 20384393
Drug: Duloxetine 20-60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 20-60 mg once or twice daily in phase II/III trials
Trial: 18727457
Drug: 7-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day standard triple therapy
Trial: 18727457
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy plus L. reuteri
Trial: 18727457
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy plus probiotic mixture
Trial: 18727457
Drug: 14-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day standard triple therapy plus probiotic mixture
Trial: 15999046
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (1 g of methylprednisolone before surgery and 4 mg of dexamethasone every 6 hours for 1 day after surgery)
Trial: 10636535
Drug: Tirofiban and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban and unfractionated heparin (n=27)
Trial: 10636535
Drug: Tirofiban and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban and unfractionated heparin
Trial: 7181738
Drug: Isocaloric diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric diet with 400 mg cholesterol and 0.8 polyunsaturated-to-saturated fat ratio
Trial: 27495968
Drug: Standard surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgery plus standard voice therapy
Trial: 27495968
Drug: Voice Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice Therapy Expulsion
Trial: 25847554
Drug: Combination (900mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (900mg Black seeds and 1.5g Turmeric/day)
Trial: 21443724
Drug: Repetitive rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive rectal painful distention (RRD)
Trial: 21443724
Drug: Intravenous CRF
RxNorm normalized name: CRF
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CRF (100 µg)
Trial: 19234822
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg IV ramosetron
Trial: 19234822
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg oral ramosetron
Trial: 15738933
Drug: Post-treatment phone
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment phone contact (experimental group)
Trial: 12423848
Drug: Water-soluble gel
RxNorm normalized name: WATER SOLUBLE BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-soluble gel lubricant
Trial: 1707221
Drug: Metformin (placebo)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (placebo)
Trial: 6814470
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate (30 mg)
Trial: 6814470
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate (60 mg)
Trial: 6814470
Drug: +/--glaucine phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +/--glaucine phosphate (60 mg)
Trial: 6814470
Drug: +/--glaucine phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +/--glaucine phosphate (30 mg)
Trial: 27392909
Drug: Conventional lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional lipid lowering drugs (Group C)
Trial: 24721903
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon α (IFNα) treatment
Trial: 21068719
Drug: Iomazenil (3.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomazenil (3.7 μg administered intravenously over 10 min)
Trial: 18397193
Drug: Functional exercise
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional exercise training (supervised by a physical therapist, three times weekly for 4 months)
Trial: 17450980
Drug: 10-week, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-week, 3 days/week weight-training treatment
Trial: 12488953
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose tolerance test
Trial: 12488953
Drug: Islet-cell antibody
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islet-cell antibody greater than 20 JDFU
Trial: 12488953
Drug: Insulin autoantibodies
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin autoantibodies
Trial: 9690691
Drug: Ipsapirone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone 50 mg once daily
Trial: 9690691
Drug: Ipsapirone 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone 30 mg once daily
Trial: 8006249
Drug: Angina-guided medical
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angina-guided medical therapy
Trial: 7642847
Drug: Ischemia-guided medical
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ischemia-guided medical therapy
Trial: 2750268
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera B subunit-whole cell vaccine (BS-WC)
Trial: 2750268
Drug: Killed whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed whole cell vaccine (WC)
Trial: 2750268
Drug: Common antigens
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common antigens in vaccines and Vibrionaceae strains
Trial: 28330592
Drug: twice-weekly deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice-weekly deep TMS (dTMS) continuation treatment for up to 12 weeks
Trial: 10226398
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) 50 mgs in divided doses with radiation (6000 cGy in six weeks)
Trial: 2653876
Drug: Nifedipine (double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (double dose)
Trial: 2653876
Drug: Nifedipine (sublingual)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (sublingual)
Trial: 27055521
Drug: GSK2586184 (50-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586184 (50-400 mg, oral, twice daily for 12 weeks)
Trial: 27055521
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, twice daily for 12 weeks)
Trial: 18474451
Drug: Effleurage massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effleurage massage therapy (20 min of effleurage on ten occasions)
Trial: 15598944
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m(2) every 3 weeks (Dq3w)
Trial: 15598944
Drug: docetaxel 40
RxNorm normalized name: docetaxel 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel 40 mg/m(2) given weekly for 6 weeks followed by 2 weeks of rest (Dqw)
Trial: 7866080
Drug: Homoeopathic medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Homoeopathic medicines
Trial: 2680794
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg orally
Trial: 25982539
Drug: Secukinumab retreatment
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab retreatment as needed (300 mg)
Trial: 25982539
Drug: Secukinumab retreatment
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab retreatment as needed (150 mg)
Trial: 25982539
Drug: Secukinumab fixed
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab fixed interval (300 mg)
Trial: 25982539
Drug: Secukinumab fixed
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab fixed interval (150 mg)
Trial: 23551359
Drug: Budesonide/formoterol 160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 160/4.5 μg two inhalations twice daily via Turbuhaler®
Trial: 23551359
Drug: Formoterol 4.5
RxNorm normalized name: BUDESONIDE 80/FORMOTEROL 4.5MCG 60D INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 4.5 μg two inhalations twice daily via Turbuhaler®
Trial: 8118901
Drug: Nonsurgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical therapy
Trial: 17633357
Drug: Sequential Colon
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Colon Dialysis (SCD)
Trial: 9515561
Drug: L-NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (3 mg/kg bolus over 5 minutes followed by continuous i.v. infusion of 50 microg/kg/min over 75 minutes)
Trial: 24326967
Drug: Deep sclerectomy
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sclerectomy with mitomycin C 0.2 mg/mL
Trial: 24326967
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with mitomycin C 0.2 mg/mL
Trial: 16444435
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg/day, for 12 weeks)
Trial: 12859311
Drug: Levobupivacaine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 1.5 mg/ml, 10 ml/h (n = 26)
Trial: 12859311
Drug: Levobupivacaine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 5 mg/ml, 3 ml/h (n = 33)
Trial: 12859311
Drug: Levobupivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 7.5 mg/ml, 2 ml/h (n = 31)
Trial: 3900393
Drug: Diflunisal high
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diflunisal high dose (1000 mg daily)
Trial: 3900393
Drug: Diflunisal low
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diflunisal low dose (750 mg daily)
Trial: 3900393
Drug: Diflunisal (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (both doses)
Trial: 3900393
Drug: Diflunisal high
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diflunisal high dose vs low dose
Trial: 30615231
Drug: Metformin 1g
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1g
Trial: 27480654
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine 10 ml (Group A)
Trial: 27480654
Drug: 0.25% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% ropivacaine 20 ml (Group B)
Trial: 25766415
Drug: Everolimus (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (5-10 mg/day)
Trial: 17879544
Drug: Zhongfu Hypotension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhongfu Hypotension Capsule (ZHC) - 3 capsules (0.5 g/capsule) twice a day for 4 weeks
Trial: 17879544
Drug: Lotensin Tablet
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lotensin Tablet - 1 tablet (10 mg/tab.) once a day for 4 weeks
Trial: 15730353
Drug: Active medications
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medications (specific medications not detailed)
Trial: 15730353
Drug: Active medications
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medications and Placebo
Trial: 12142119
Drug: HERG K897T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HERG K897T polymorphism (genotypes AC or CC)
Trial: 375433
Drug: Gentamicin and
RxNorm normalized name: Gentamicin and prednisolone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin and penicillin (60 mg/m2/8 h)
Trial: 375433
Drug: Gentamicin (constant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (constant vs intermittent infusion)
Trial: 25485782
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2/3 h), carboplatin (AUC 5), and bevacizumab (15 mg/kg) administered every 21 days for 6-8 cycles, followed by maintenance therapy with bevacizumab (15 mg/kg) every 21 days for 16 cycles.
Trial: 25485782
Drug: Paclitaxel, carboplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel, carboplatin, and bevacizumab combination therapy.
Trial: 17318618
Drug: Ibuprofen (5%)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (5%)
Trial: 17318618
Drug: Arnica (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arnica (50 g tincture/100 g, DER 1:20)
Trial: 11252073
Drug: Creatine (CR;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (CR; 20 g.d‐1, 5 d)
Trial: 16709303
Drug: budesonide/formoterol 160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide/formoterol 160/4.5 microg, one inhalation, once or twice daily maintenance plus additional doses as needed (1 x SMART or 2 x SMART)
Trial: 16709303
Drug: budesonide/formoterol 160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide/formoterol 160/4.5 microg two inhalations twice daily plus formoterol 4.5 microg as needed (2 x 2 FIX + F)
Trial: 7877117
Drug: Trimipramine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine with adjunct sleep deprivation (SD)
Trial: 7877117
Drug: Trimipramine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine with adjunct bright light (BL)
Trial: 3182456
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg x 2 daily)
Trial: 3182456
Drug: Pivampicillin (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin (700 mg x 3 daily)
Trial: 27869354
Drug: Olopatadine hydrochloride
RxNorm normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine hydrochloride 0.1% twice a day
Trial: 27869354
Drug: Emedastine difumarate
RxNorm normalized name: Emedastine Difumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emedastine difumarate 0.05% twice a day
Trial: 23140547
Drug: Ranolazine 375
RxNorm normalized name: Ranolazine 375 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge
Trial: 19886513
Drug: Weekly folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly folic acid (5,000 or 2,800 microg) plus iron, zinc, and vitamin B-12 for 12 weeks
Trial: 19886513
Drug: Daily folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily folic acid (400 or 200 microg) plus iron, zinc, and vitamin B-12 for 12 weeks
Trial: 9217033
Drug: Letrozole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 0.5 mg per day
Trial: 9217033
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg per day
Trial: 3064085
Drug: ZK 93426
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 93426 (benzodiazepine receptor antagonist with weak inverse agonist properties)
Trial: 29637820
Drug: hUCB‐MSC infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hUCB‐MSC infusion (4 infusions at a fixed dose of 5 × 10^7) with basic rehabilitation
Trial: 29637820
Drug: hUCB‐MSC infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hUCB‐MSC infusion
Trial: 25641606
Drug: Vortioxetine 10
RxNorm normalized name: vortioxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10 mg/day for 14 days coadministered with aspirin 150 mg/day for 6 days
Trial: 25641606
Drug: Vortioxetine 10
RxNorm normalized name: vortioxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10 mg/day for 14 days with maintenance warfarin (1-10 mg)
Trial: 18416081
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus shenqi fuzheng injection
Trial: 16858933
Drug: Bedtime calcium
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime calcium supplementation (2 calcium carbonate tablets, 334 mg per tablet)
Trial: 12032788
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg loading dose of aminophylline
Trial: 12032788
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg loading dose of aminophylline
Trial: 8529534
Drug: Oral nalmefene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nalmefene glucuronide
Trial: 2905636
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ketorolac tromethamine
Trial: 2227078
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac tromethamine
Trial: 150487
Drug: Levamisole (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (continuous administration for 16 weeks)
Trial: 12207836
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg twice/d) and Vitamin E (100 mg twice/d) for 12 weeks
Trial: 26790705
Drug: G‐CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (10 µg/kg for five days)
Trial: 24886264
Drug: Proactive telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive telephone peer support (two calls within the first ten days postpartum, then weekly calls until week twelve, with continued contact until six months postpartum)
Trial: 20973465
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (Sprinkles) - 60 sachets (12.5 mg elemental iron) taken daily for 2 months
Trial: 12534637
Drug: Aminophylline (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (mean rate 9.2 +/- 2.6 micro g kg‐1 min‐1)
Trial: 24894386
Drug: Levosimendan (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.05 to 0.2 μg.kg⁻¹.min⁻¹ for 24 hours)
Trial: 21194606
Drug: 300-mg test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg test formulation of rifampicin
Trial: 21194606
Drug: 150-mg reference
RxNorm normalized name: pramoxine
DrugBank: Pramocaine (DB09345)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150-mg reference formulation of rifampicin
Trial: 21194606
Drug: 300-mg test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg test formulation of 25-desacetyl rifampicin
Trial: 21194606
Drug: 150-mg reference
RxNorm normalized name: pramoxine
DrugBank: Pramocaine (DB09345)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150-mg reference formulation of 25-desacetyl rifampicin
Trial: 10197802
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin (AmBisome) 2 mg/kg three times weekly
Trial: 7556234
Drug: Norfloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (200 mg/day)
Trial: 26095068
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk product containing probiotic (FMPP) 65 mL/day for 6 weeks
Trial: 26095068
Drug: Open-label FMPP
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label FMPP treatment
Trial: 26095068
Drug: Withdrawal phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Withdrawal phase after open-label FMPP treatment
Trial: 24285428
Drug: Menaquinone-7 (MK-7)
RxNorm normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menaquinone-7 (MK-7) 360 µg thrice weekly for 8 weeks